RCUS Q2 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+7.4% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$83M-286.2% margin

Net Income

-$75M-258.6% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+16.0%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$62M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$654M

Stockholders' Equity

$566M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$27M	+7.4%
Gross Profit	$29M	$27M	+7.4%
Operating Income	-$83M	-$69M	-20.3%
Net Income	-$75M	-$67M	-11.9%

Revenue Segments

License and Development Services Revenue

$19M66%

Other Collaboration Revenue

$10M34%